Patents by Inventor Ching-Jun Liou

Ching-Jun Liou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8367811
    Abstract: A radioactive material containing chitosan for inhibiting cancer and a preparation method thereof are revealed. The adioactive material containing chitosan is formed by using SOCTA chelating agent to connect chitosan and radionuclides such as 188Re, and Tc-99m etc. The preparation method of the radioactive material containing chitosan includes the steps of: prepare SOCTA-Chitosan compound; and prepare M(radionuclide)-SOCTA-Chitosan compound. By biocompatibility and clotting in alkaline environment of human blood of chitosan, the radioactive material containing chitosan is injected into cancer and staying there for a long time so as to achieve effectively treatment.
    Type: Grant
    Filed: November 3, 2008
    Date of Patent: February 5, 2013
    Assignee: Atomic Energy Council-Institute of Nuclear Energy Research
    Inventors: Tsai-Yueh Luo, I-Chung Tang, Jian-Wen Chen, Kwei-Luen Hsu, Yu-Lung Wu, Te-Sheng Liang, Chang-Mau Sheng, Jin-Jenn Lin, Ching-Jun Liou, Jyh-Daw Sheu
  • Patent number: 8048405
    Abstract: A radioactive mixture and a manufacturing method thereof are disclosed. The radioactive mixture (188Re-MN/Lipiodol mixture) is formed by chelating reaction of MN series compounds that are amine-amide-disulfide amine quadric-dentate chelate ligands with TcO4?/or ReO4?, and then dissolved in Lipiodol. Moreover, the 99mTc/or 188Re of the TcO4?/or ReO4? avoids bone marrow injuries caused by free 90Y. By the feature of the Lipiodol that stays in liver tumors for a long period, the radioactive mixture is applied to treat liver cancers by injection so that injuries caused by surgical operations can be prevented. 188Re-MN/Lipiodol is used for liver cancer, breast cancer or other solid tumors treatment. Re-188 MN or Re-188 MN/Lipiodol can be mixed with anticancer drugs, hydrogel, liposome, micelle or other nano-particles to form the multifunctional therapeutic modality.
    Type: Grant
    Filed: January 16, 2009
    Date of Patent: November 1, 2011
    Assignee: Atomic Energy Council-Institute of Nuclear Energy Research
    Inventors: Tsai-Yueh Luo, I-Chung Tang, Show-Wen Liu, Yu-Lung Wu, Cheng-Hsien Lin, Cheng-Fang Hsu, Kwei-Luen Hsu, Chang-Mau Sheng, Ching-Jun Liou, Te-Sheng Liang
  • Publication number: 20100183508
    Abstract: A radioactive mixture and a manufacturing method thereof are disclosed. The radioactive mixture (188Re-MN/Lipiodol mixture) is formed by chelating reaction of MN series compounds that are amine-amide-disulfide amine quadric-dentate chelate ligands with TcO4?/or ReO4?, and then dissolved in Lipiodol. Moreover, the 99mTc/or 188Re of the TcO4?/or ReO4? avoids bone marrow injuries caused by free 90Y. By the feature of the Lipiodol that stays in liver tumors for a long period, the radioactive mixture is applied to treat liver cancers by injection so that injuries caused by surgical operations can be prevented. 188Re-MN/Lipiodol is used for liver cancer, breast cancer or other solid tumors treatment. Re-188 MN or Re-188 MN/Lipiodol can be mixed with anticancer drugs, hydrogel, liposome, micelle or other nano-particles to form the multifunctional therapeutic modality.
    Type: Application
    Filed: January 16, 2009
    Publication date: July 22, 2010
    Inventors: Tsai-Yueh LUO, I-Chung Tang, Show-Wen Liu, Yu-Lung Wu, Cheng-Hsien Lin, Cheng-Fang Hsu, Kwei-Luen Hsu, Chang-Mau Sheng, Ching-Jun Liou, Te-Sheng Liang
  • Publication number: 20100111860
    Abstract: A radioactive material containing chitosan for inhibiting cancer and a preparation method thereof are revealed. The adioactive material containing chitosan is formed by using SOCTA chelating agent to connect chitosan and radionuclides such as 188Re, and Tc-99m etc. The preparation method of the radioactive material containing chitosan includes the steps of: prepare SOCTA-Chitosan compound; and prepare M(radionuclide)-SOCTA-Chitosan compound. By biocompatibility and clotting in alkaline environment of human blood of chitosan, the radioactive material containing chitosan is injected into cancer and staying there for a long time so as to achieve effectively treatment.
    Type: Application
    Filed: November 3, 2008
    Publication date: May 6, 2010
    Inventors: Tsai-Yueh LUO, I-Chung Tang, Jian-Wen Chen, Kwei-Luen Hsu, Yu-Lung Wu, Te-Sheng Liang, Chang-Mau Sheng, Jin-Jenn Lin, Ching-Jun Liou, Jyh-Daw Sheu
  • Publication number: 20070258885
    Abstract: A device for concentrating 99mTc pertechnetate and a method thereof are disclosed. The device includes a concentration device, a control device and a central processing unit. The concentration device is for concentrating 99mTc pertechnetate, the control device connects with each members of the concentration device, and the central processing unit is used for saving an automatic control program. The automatic control program is run by the central processing unit so as to detect and monitor weight as well as activity of the concentrated 99mTc pertechnetate. Due to the automatical control, the concentration quality and production efficiency of the 99mTc pertechnetate are improved. Moreover, the radiation dose received by users is reduced.
    Type: Application
    Filed: May 8, 2006
    Publication date: November 8, 2007
    Inventors: Tsai-Yueh Luo, Ai-Ren Lo, Wuu-Jyh Lin, Tseng-Chung Huang, Bor-Tsung Hsieh, Ching-Jun Liou